Researcher
Steven Simoens
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Jul 2013 → Today
Projects
1 - 10 of 22
- How to create sustainable market access to advanced therapies?From1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Health Economic Evaluations of Preventive Policies in Flanders (HELPPFL)From22 Nov 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Exploring the market access of advanced therapy medicinal products (ATMPs)From17 Oct 2022 → 9 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: STRADA-CEF trial.From1 Oct 2022 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Exploring the market environment of biologics including biosimilar medicinesFrom20 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Framework for value driven market access of gene therapyFrom1 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Unlocking Biosimilar Benefits: An Exploration of Barriers to Biosimilar Adoption, Value Assessment and Market SustainabilityFrom16 Oct 2019 → 13 Dec 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- A Belgian policy framework for best-value biological medicinesFrom3 Sep 2019 → 18 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Framework for value driven market access of gene therapyFrom1 Sep 2019 → 23 Oct 2020Funding: FWO Strategic Basic Research Grant
Publications
21 - 30 of 428
- What matters most to patients with multiple myeloma? A Pan-European patient preference study(2022)
Authors: Rosanne Janssens, Elise Schoefs, Michel Delforge, Martina Vandebroek, Steven Simoens, Isabelle Huys
- Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies(2022)
Authors: Steven Simoens
- Determinants of prescribing decisions for off-patent biological medicines in Belgium: a qualitative study(2022)
Authors: Yannick Vandenplas, Steven Simoens, Arnold Vulto, Isabelle Huys
- How to balance valuable innovation with affordable access to medicines in Belgium?(2022)
Authors: Steven Simoens, Khadidja Abdallah, Liese Barbier, Teresa Barcina Lacosta, Alessandra Blonda, Elif Car, Evelien De Sutter, Rosanne Janssens, Teodora Lalova-Spinks, Robbe Saesen, et al.
- How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries(2022)
Authors: Alessandra Blonda, Yvonne Denier, Isabelle Huys, Steven Simoens
- Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking(2022)
Authors: Liese Barbier, Steven Simoens, Paul Declerck, Arnold Vulto, Isabelle Huys
- Critical Reflections on Reimbursement and Access of Advanced Therapies(2022)
Authors: Steven Simoens
- Emerging Insights into European Markets of Biologics, Including Biosimilars(2022)
Authors: Steven Simoens, Isabelle Huys
- How much do the public sector and the private sector contribute to biopharmaceutical R&D?(2022)
Authors: Steven Simoens, Isabelle Huys
Pages: 939 - 945 - Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging(2022)
Authors: Liese Barbier, Steven Simoens, Paul Declerck, Arnold Vulto, Isabelle Huys